The pharmaceutical industry has an extraordinary role in the manufacturing of medications and vaccines to counter diseases, manage and enhance the quality of life of people. The main focus of the pharmaceutical industry is into the advancements of the technology through innovations, research meeting the demands of the people. This industry directly affects the health of the global population, so many international regulatory bodies monitor aspects like patents, quality, drug safety, quality, and price. A few regulatory bodies are FDA, WHO, MHRA. The market of pharma has dealt with most rising deals in the last decade base on researches, technology, infrastructures in the bioscience field. The global market of pharmacy is intended to rise at 4.9% to $13 trillion by 2020. The US market is expected to grow to $320 billion by 2020. The 3rd largest Japan market has forecasted growth by 3% while the US has 5.6%. The market of pharma has emerged into a vast empire globally.
The current state of the pharmaceutical industry arises many questions thinking about it, as to why is there is a lot of increase in the pharmaceutical industry, the modern medications are complex, factors that led to the pharmaceutical industry.
The growth drivers in the pharmaceutical industry are aging population, rise in chronic disease and changing lifestyle and increased growth of income by people. Apart from these, due to the growth of urbanization and globalization, it led to many environmental impacts. This led to the growth in demand for better health, and its supplements for every group and area.
What makes it a kind differed?
This industry functions like other departments with raw materials, production, finished goods, marketing, and consumers. It is more regulated by the regulatory bodies and the captive intense than others.
Top Leading Pharma Companies
The pharmaceutical industry has always been under the spotlight and the company names turn up based on the yearly sales. The top 5 names of pharmaceutical industries are:
Johnson & Johnson
Merck & Co
This is the world’s largest pharmaceutical company, which is an American multinational company, having its headquarters in Connecticut, USA. Its revenue has reached $53.6 billion helping the growth of about 2%. This company is a research-based company expanding its roots in various other divisions like oncology, immunology, neurosciences and other rare diseases. Pfizer had a successful 2018 year along with good revenue. It has received many approvals for the medication by USFDA in oncology and many other patent protection is left. The most key products from Pfizer includes Xeljanz, Eliquis, and Ibrance. It has also the portfolio of biologics, vaccines, small molecule medications and other products.
This is a Swiss Pharmaceutical company, leading as the 2nd largest company having 94,442 employees globally. This company firm is into the developing innovative drugs of oncology, infectious diseases, immunology, and neuroscience. The multinational company with a growth rate of 2.7% and the top 3 products shared over 40% of Roche’s total revenue in 2018 ($57.2 bn). Roche’s best-selling drugs Herceptin, Avastin and Rituxan are the world’s top cancer drugs. The CEO “Severan Schwan”, has reported that new medicines have accounted for 90% of the company’s growth in the year 2018. The launch of Ocrevus was the most successful one in its (Roche’s) history.
Johnson & Johnson
This company has been established for over 130 years and has become the most predominant one. It has occupied the 3rd place among the world pharma ranking. This has become popular for household consumer goods like Neutrogena, Listerine, and Aveeno. The growth was 12.1% overall, because of the production of Actelion in 2017, having a 3.4% increase. The best-selling drugs from J&J were Darzalex, Zytiga, and Stelara. The total earnings of the company are the US $40.7 million.
This is a French pharmaceutical company in the 4th position having its headquarters in Paris, France. with the growth of 7.1%.in its earnings in the pharmaceutical sector, which is a substantial percentage of the company’s total revenue. The 25% revenue is from the best of Sanofi drugs being sold Lantus which is a diabetic injection, Lovenox an anticoagulant and Aubagio the best for multiple sclerosis. The total revenue of Sanofi is US $39.3 million.
Merck & Co.
This is an American multinational pharmaceutical industry in the 5th position globally and is headquartered in New Jersey. Merck is known by Merck Sharp & Dohme (MSD) outside the US and Canada. The company is into drugs, vaccines, biologics, cardiovascular, endocrinology, oncology, infectious diseases. Merck & Co saw a rise of 12.2% growth in the revenue from 2017, leading to the boosted success of its best-sold drugs HPV vaccine Gardasil, Diabetic pills Januvia and cancer immunotherapy drug Keytruda. The company has its earnings of US $37.7 billion. It has started the biologic license submission process at USFDA in 2018. This application was for investigational vaccine V920, to fight Zaire strain, of the Ebola virus. First of its vaccines were for the mumps, rubella viruses, which were developed by the Merck scientist, Maurice Hilleman. He has also developed the vaccination for Hepatitis B. and Varicella for chickenpox.
Novartis is a Switzerland based pharmaceutical company having its HQ in Basel. It has 3 operating divisions namely, Innovative medicines, Sandoz(generics), Alcon(eye care). The company’s global research operations known as the ‘Novartis Institutes for Biomedical Research’ has its global headquarters in Cambridge, Massachusetts, US. The company works on a broader range of medications of oncology, immunology, dermatology, respiratory and neuroscience fields. The revenue has risen to 5.8% in 2017. The total revenue was US $ 34.9 billion. The company has invested in most market generic drugs as competition on oncology medications Gleevec, BP medications Diovan and Exforge. It has spent 18% of its revenue on the R&D in 2018, to combat the losses on above generic drugs. Gilenya, for multiple sclerosis and Lucentis for eye-degenerative diseases, are the most and best-selling drugs from Novartis.
AbbVie is a biopharmaceutical and American based company found in 2013 and origin is a spin-off of Abbott laboratories. It has its HQ at Illinois, US. It has an impressive revenue growth of 16.2% in 2017. It has announced the Upadacitinib, most anticipated drug for treating moderate to severe atopic dermatitis has been grated by the USFDA. AbbVie spans multiple therapy drugs in areas like oncology, dermatology, neurology, gastroenterology. The top-selling drugs are Humira and Imbruvica cancer-treating drugs. The company has a revenue of US $32.8 billion.
It is an American biopharmaceutical company having its HQ at the Thousand Oaks, California, US. Neulasta, an immunostimulatory drug against infections for the cancer patients and Enbrel a tumor necrosis factor blocker for treating rheumatoid arthritis are the best-selling product. A few other products are, XGEVA, Prolia, Vectibix, Nplate, Aranesp, Epogen, Mimpara, etc. The main focus of the company is molecular biology and biochemistry providing a health-based market on rDNA technology. Amgen has seen the best revenue from the products of Repatha, BLINCYTO, and Prolia. The revenue is estimated as the US $23.7 as per 2018.
This is a British multinational pharmaceutical, biotechnological and consumer goods industry and has its HQ at Brentford, London, UK. It was founded in the year 2000. The revenue is US $23 billion in 2018. It has an employee strength of 98,462 as per 2017. The most successful drugs are in the fields of HIV/AIDS, vaccines and respiratory. The company has a 2% rise in the revenue as per 2017, where the sales were more from the Tivicay and Triumeq, the Ellipta inhaler used for asthma, COPD and Nucala. GSK has the key approvals for the Shingrix, to treat the shingles virus, was successful in reaching a good revenue of £784 million.
Bristol-Myers Squibb (BMS)
This is an American based multinational pharmaceutical company. It has its HQ at the NYC, US. The company has its products manufacturing in prescription pharmaceuticals and biologics in the areas of cardiovascular, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, and psychiatric disorders. The company has its R&D centers are at New Jersey, New York, Cambridge, Massachusetts, Ireland, Belgium, India, Tokyo, Japan. The rise of revenue was on the sales of Opdivo (cancer) Eliquis (blood thinner). The company planned the acquisition of Celgene- an innovative drug of Oncology Biotech in 2019. The total revenue is US $ 22.6 billion. About 23,300 employees are working in this company globally.